Cited by 370SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Open access

Winkler, Emma S., Gilchuk, Pavlo, Yu, Jinsheng, Bailey, Adam L., Chen, Rita E., Chong, Zhenlu, Zost, Seth J., Jang, Hyesun, Huang, Ying, Allen, James D., Case, James Brett, Sutton, Rachel E., Carnahan, Robert H., Darling, Tamarand L., Boon, Adrianus C.M., Mack, Matthias, Head, Richard D., Ross, Ted M., Crowe, James E., Diamond, Michael S.·2021·Cell

DOI 10.1016/j.cell.2021.02.026PMC PMC7879018

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism of action in vivo is incompletely understood. Here, we define correlates of protection of neutralizing human monoclonal antibodies (mAbs) in SARS-CoV-2-infected animals. Whereas Fc effector functions are dispensable when representative neutralizing mAbs are administered as prophylaxis, they are required for optimal protection as therapy. When given after infection, intact mAbs reduce SARS-CoV-2 burden and lung disease in mice and hamsters better than loss-of-function Fc variant mAbs. Fc engagement of neutralizing antibodies mitigates inflammation and improves respiratory mechanics, and transcriptional profiling suggests these phenotypes are associated with diminished innate immune signaling and preserved tissue repair. Immune cell depletions establish that neutralizing mAbs require monocytes and CD8+ T cells for optimal clinical and virological benefit. Thus, potently neutralizing mAbs utilize Fc effector functions during therapy to mitigate lung infection and disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2021.02.026

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Self-citation
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes
Karki, R., Sharma, B. R., Tuladhar, S., Williams, E. P., Zalduondo, L., Samir, P., Zheng, M., Sundaram, B., Banoth, B., Malireddi, R. K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.025 · Cited by 1,734
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · cited 1×
“overlapping epitopes and show differences in neutralization potency (Alsoussi et al., 2020; Cao et al., 2020; Hansen et al., 2020; Ju et al., 2020; Liu et al., 2020; Noy-Porat et al., 2020; Pinto et al., 2020; Robbiani et al., 2020; Zost et al., 2020a).”
Self-citation
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,429
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349
Self-citation
Pathogenesis and transmission of SARS-CoV-2 in golden hamsters
Sia, S. F., Yan, L.-M., Chin, A. W. H., Fung, K., Choy, K.-T., Wong, A. Y. L., Kaewpreedee, P., Perera, R. A. P. M., Poon, L. L. M., Nicholls, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2342-5 · Cited by 1,342
TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection.
Serbina, N., Salazar-Mather, T. P., Biron, C., Kuziel, W., & Pamer, E. (2003) · Immunity · doi:10.1016/s1074-7613(03)00171-7 · Cited by 1,293
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · cited 8×
“Prophylactic and therapeutic efficacy of anti-SmAbs has been demonstrated in vivo in murine, hamster, and non-human primate models of SARS-CoV-2 pathogenesis (Alsoussi et al., 2020; Baum et al., 2020; Fagre et al., 2020; Hansen et al., 2020; Hassan et al., 2020; Kreye et al., 2020; Rogers et al., 2020; Shi et al., 202…”
BackgroundMethodResultInfluential
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041
Self-citation
Lethal Infection of K18- hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus
McCray, P. B., Pewe, L., Wohlford-Lenane, C., Hickey, M., Manzel, L., Shi, L., Netland, J., Jia, H. P., Halabi, C., Sigmund, C. D., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02012-06 · Cited by 1,010
Monocyte differentiation and antigen-presenting functions
Jakubzick, C. V., Randolph, G. J., & Henson, P. M. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.28 · Cited by 910 · cited 1×
“Circulating CCR2 monocytes can differentiate into myeloid cell subsets including interstitial macrophages and monocyte-derived CD11b dendritic cells following migration to the lung (Jakubzick et al., 2017).”
SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function
Winkler, E. S., Bailey, A. L., Kafai, N. M., Nair, S., McCune, B. T., Yu, J., Fox, J. M., Chen, R. E., Earnest, J. T., Keeler, S. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0778-2 · Cited by 901 · cited 3×
“In the stringent K18-hACE2 model of SARS-CoV-2 pathogenesis (Golden et al., 2020; Winkler et al., 2020), we defined minimum serum neutralizing titers (NT50) and concentrations of 104 and 212 ng/ mL for the prevention of weight loss and 381 and 851 ng/mL for reduction of viral burden in the lung.”
Self-citation
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J. M., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 891
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.106 · Cited by 862
Flow Cytometric Analysis of Macrophages and Dendritic Cell Subsets in the Mouse Lung
Misharin, A. V., Morales-Nebreda, L., Mutlu, G. M., Budinger, G. R. S., & Perlman, H. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0086ma · Cited by 838
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C. S. C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 824
Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo
DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749
The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 735
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Leist, S. R., Dinnon, K. H., Schäfer, A., Tse, L. V., Okuda, K., Hou, Y. J., West, A., Edwards, C. E., Sanders, W., Fritch, E. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.050 · Cited by 613
Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses
Liu, R., Holik, A. Z., Su, S., Jansz, N., Chen, K., Leong, H. S., Blewitt, M. E., Asselin-Labat, M.-L., Smyth, G. K., & Ritchie, M. E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv412 · Cited by 583
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
Baum, A., Ajithdoss, D., Copin, R., Zhou, A., Lanza, K., Negron, N., Ni, M., Wei, Y., Mohammadi, K., Musser, B., et al. (2020) · Science · doi:10.1126/science.abe2402 · Cited by 517
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2014) · Cell · doi:10.1016/j.cell.2014.08.023 · Cited by 502
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies
Hassan, A. O., Case, J. B., Winkler, E. S., Thackray, L. B., Kafai, N. M., Bailey, A. L., McCune, B. T., Fox, J. M., Chen, R. E., Alsoussi, W. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.011 · Cited by 482
Self-citation
A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge
Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477
Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice
Mack, M., Cihak, J., Simonis, C., Luckow, B., Proudfoot, A. E. I., Plachý, J., Brühl, H., Frink, M., Anders, H., Vielhauer, V., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.7.4697 · Cited by 459
Self-citation
Effects of microbiota-directed foods in gnotobiotic animals and undernourished children
Gehrig, J. L., Venkatesh, S., Chang, H.-W., Hibberd, M. C., Kung, V. L., Cheng, J., Chen, R. Y., Subramanian, S., Cowardin, C. A., Meier, M. F., et al. (2019) · Science · doi:10.1126/science.aau4732 · Cited by 431
Self-citation
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0998-x · Cited by 429
Self-citation
Cell Surface Recycling of Internalized Antigen Permits Dendritic Cell Priming of B Cells
Bergtold, A., Desai, D. D., Gavhane, A., & Clynes, R. (2005) · Immunity · doi:10.1016/j.immuni.2005.09.013 · Cited by 417
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
DiLillo, D. J., Palese, P., Wilson, P. C., & Ravetch, J. V. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84428 · Cited by 410
Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice
Sapparapu, G., Fernández, E., Kose, N., Cao, B., Fox, J. M., Bombardi, R. G., Zhao, H., Nelson, C. A., Bryan, A. L., Barnes, T., et al. (2016) · Nature · doi:10.1038/nature20564 · Cited by 410
Self-citation
Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice
Subbarao, K., McAuliffe, J. M., Vogel, L., Fahle, G. A., Fischer, S. H., Tatti, K. M., Packard, M. M., Shieh, W., Zaki, S. R., & Murphy, B. R. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3572-3577.2004 · Cited by 397
Modulation of Immune Complex–induced Inflammation In Vivo by the Coordinate Expression of Activation and Inhibitory Fc Receptors
Clynes, R., Maizes, J. S., Guinamard, R., Ono, M., Takai, T., & Ravetch, J. V. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.1.179 · Cited by 387
Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo
Lu, C.-L., Murakowski, D. K., Bournazos, S., Schoofs, T., Sarkar, D., Halper-Stromberg, A., Horwitz, J. A., Nogueira, L., Golijanin, J., Gazumyan, A., et al. (2016) · Science · doi:10.1126/science.aaf1279 · Cited by 357
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Laczko, D. I., Hogan, M. J., Toulmin, S. A., Hicks, P. D., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.019 · Cited by 355
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model
Kreye, J., Reincke, S. M., Kornau, H.-C., Sánchez-Sendin, E., Corman, V. M., Liu, H., Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.049 · Cited by 347
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 321
Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767749 · Cited by 317
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P. T., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 305
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
Schäfer, A., Muecksch, F., Lorenzi, J. C. C., Leist, S. R., Cipolla, M., Bournazos, S., Schmidt, F., Maison, R. M., Gazumyan, A., Martinez, D. R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201993 · Cited by 305
Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M. D., Burke, J., Yu, J., Feldman, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.052 · Cited by 297
Self-citation
Monoclonal Antibodies for Prevention and Treatment of COVID-19
Marovich, M., Mascola, J. R., & Cohen, M. S. (2020) · JAMA · doi:10.1001/jama.2020.10245 · Cited by 272
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Tostanoski, L. H., Wegmann, F., Martinot, A. J., Loos, C., McMahan, K., Mercado, N. B., Yu, J., Chan, C. N., Bondoc, S., Starke, C. E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1070-6 · Cited by 270
Self-citation
Fc receptors in antibody‐dependent enhancement of viral infections
Taylor, A., Foo, S., Bruzzone, R., Dinh, L. V., King, N. J. C., & Mahalingam, S. (2015) · Immunological Reviews · doi:10.1111/imr.12367 · Cited by 256
COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes
Sánchez‐Cerrillo, I., Landete, P., Orzaiz, B. A., Sánchez‐Alonso, S., Sánchez-Azofra, A., Marcos‐Jiménez, A., Ávalos, E., Alcaraz‐Serna, A., Santos, I. D. L., Mateu‐Albero, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140335 · Cited by 250
Growth, detection, quantification, and inactivation of SARS-CoV-2
Case, J. B., Bailey, A. L., Kim, A. S., Chen, R. E., & Diamond, M. (2020) · Virology · doi:10.1016/j.virol.2020.05.015 · Cited by 234
Self-citation
Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers
Fibriansah, G., Ibarra, K. D., Ng, T., Smith, S. A., Tan, J. L., Lim, X.-N., Ooi, J. S. G., Kostyuchenko, V. A., Wang, J., de Silva, A. M., et al. (2015) · Science · doi:10.1126/science.aaa8651 · Cited by 230
Self-citation
Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection
Rosenke, K., Meade-White, K. D., Letko, M. C., Clancy, C. S., Hansen, F., Liu, Y., Okumura, A., Tang-Huau, T.-L., Li, R., Saturday, G. A., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1858177 · Cited by 216
Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease
Golden, J. W., Cline, C. R., Zeng, X., Garrison, A. R., Carey, B. D., Mucker, E. M., White, L. E., Shamblin, J. D., Brocato, R. L., Liu, J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142032 · Cited by 200
Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells
Chng, J., Wang, T., Nian, R., Lau, A., Hoi, K. M., Ho, S. C., Gagnon, P., Bi, X., & Yang, Y. (2015) · mAbs · doi:10.1080/19420862.2015.1008351 · Cited by 196
Immunological Lessons from Respiratory Syncytial Virus Vaccine Development
Ruckwardt, T. J., Morabito, K. M., & Graham, B. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.007 · Cited by 185
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000583 · Cited by 181
Self-citation
Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG
Amigorena, S., Salamero, J., Davoust, J. M., Fridman, W. H., & Bonnerot, C. (1992) · Nature · doi:10.1038/358337a0 · Cited by 174
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice
He, W., Chen, C.-J., Mullarkey, C. E., Hamilton, J. R., Wong, C. K., Leon, P. E., Uccellini, M. B., Chromikova, V., Henry, C., Hoffman, K. W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00928-3 · Cited by 168
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
Niessl, J., Baxter, A. E., Mendoza, P., Janković, M., Cohen, Y. Z., Butler, A. L., Lu, C.-L., Dubé, M., Shimeliovich, I., Gruell, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0747-1 · Cited by 168
Cellular receptors for animal viruses
Lentz, T. L. (1995) · Trends in Microbiology · doi:10.1016/s0966-842x(00)88967-2 · Cited by 161
Cooperativity Between CD8+ T Cells, Non-Neutralizing Antibodies, and Alveolar Macrophages Is Important for Heterosubtypic Influenza Virus Immunity
Laidlaw, B. J., Decman, V., Ali, M. A., Abt, M. C., Wolf, A. I., Monticelli, L. A., Mozdzanowska, K., Angelosanto, J., Artis, D., Erikson, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003207 · Cited by 145
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
Dhodapkar, K. M., Banerjee, D. K., Connolly, J., Kukreja, A., Matayeva, E., Veri, M. C., Ravetch, J. V., Steinman, R. M., & Dhodapkar, M. V. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062545 · Cited by 141
Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
Bournazos, S., Corti, D., Virgin, H. W., & Ravetch, J. V. (2020) · Nature · doi:10.1038/s41586-020-2838-z · Cited by 139
Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique
McGovern, T. K., Robichaud, A., Fereydoonzad, L., Schuessler, T. F., & Martin, J. G. (2013) · Journal of Visualized Experiments · doi:10.3791/50172 · Cited by 131
Poorly Neutralizing Cross-Reactive Antibodies against the Fusion Loop of West Nile Virus Envelope Protein ProtectIn Vivovia Fcγ Receptor and Complement-Dependent Effector Mechanisms
Vogt, M. R., Dowd, K. A., Engle, M. J., Tesh, R. B., Johnson, S., Pierson, T. C., & Diamond, M. (2011) · Journal of Virology · doi:10.1128/jvi.05859-11 · Cited by 131
Self-citation
A potent human neutralizing antibody Fc-dependently reduces established HBV infections
Li, D., He, W., Liu, X., Zheng, S., Qi, Y., Li, H., Mao, F., Liu, J., Sun, Y., Pan, L., et al. (2017) · eLife · doi:10.7554/elife.26738 · Cited by 122
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Noy-Porat, T., Makdasi, E., Alcalay, R., Mechaly, A., Levy, Y., Bercovich-Kinori, A., Zauberman, A., Tamir, H., Yahalom-Ronen, Y., Israeli, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18159-4 · Cited by 122
Proteomic Signatures of Heart Failure in Relation to Left Ventricular Ejection Fraction
Adamo, L., Yu, J., Resende, C. R., Javaheri, A., Head, R. D., & Mann, D. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.061 · Cited by 122
Self-citation
Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia.
Wells, M. A., Ennis, F. A., & Albrecht, P. G. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.126.3.1042 · Cited by 112
Passive antibody therapy in COVID-19
Abraham, J. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0365-7 · Cited by 110
The Challenges of Vaccine Development against a New Virus during a Pandemic
Diamond, M., & Pierson, T. C. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.021 · Cited by 108
Self-citation
Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions
Baudino, L., Shinohara, Y., Nimmerjahn, F., Furukawa, J., Nakata, M., Martínez-Soria, E., Petry, F., Ravetch, J. V., Nishimura, S., & Izui, S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6664 · Cited by 105
Negative Signaling in Fc Receptor Complexes
Daëron, M., & Lesourne, R. (2006) · Advances in immunology · doi:10.1016/s0065-2776(05)89002-9 · Cited by 97
Autonomous phagosomal degradation and antigen presentation in dendritic cells
Hoffmann, E., Kotsias, F., Visentin, G., Bruhns, P., Savina, A., & Amigorena, S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203912109 · Cited by 92
Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection
Liu, Q., Fan, C., Li, Q., Zhou, S., Huang, W., Wang, L., Sun, C., Wang, M., Wu, X., Ma, J., et al. (2017) · Scientific Reports · doi:10.1038/srep45552 · Cited by 87
Enhancing dengue virus maturation using a stable furin over-expressing cell line
Mukherjee, S., Sirohi, D., Dowd, K. A., Chen, Z., Diamond, M. S., Kuhn, R. J., & Pierson, T. C. (2016) · Virology · doi:10.1016/j.virol.2016.06.022 · Cited by 82
Self-citation
Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine
Luo, F., Liao, F., Wang, H., Tang, H.-B., Yang, Z.-Q., & Hou, W. (2018) · Virologica Sinica · doi:10.1007/s12250-018-0009-2 · Cited by 82
Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes
Fox, J. M., Roy, V., Gunn, B. M., Huang, L., Edeling, M. A., Mack, M., Fremont, D. H., Doranz, B. J., Johnson, S., Alter, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aav5062 · Cited by 79
Self-citation
Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a
Arduin, E., Arora, S., Bamert, P. R., Kuiper, T., Popp, S. L., Geisse, S., Grau, R., Calzascia, T., Zenke, G., & Kovařík, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.017 · Cited by 79
Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
Qin, E.-D., Shi, H., Tang, L., Wang, C., Chang, G., Ding, Z., Zhao, K., Wang, J., Chen, Z., Yu, M., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.038 · Cited by 75
COVID 19 Vaccines: Should we fear ADE?
Halstead, S. B., & Katzelnick, L. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa518 · Cited by 69
Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus
Renner, M., Flanagan, A., Dejnirattisai, W., Puttikhunt, C., Kasinrerk, W., Supasa, P., Wongwiwat, W., Chawansuntati, K., Duangchinda, T., Cowper, A. E., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0227-7 · Cited by 51
A Game of Numbers
Pierson, T. C., & Diamond, M. (2014) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2014.10.005 · Cited by 47
Self-citation
Differential requirements for FcγR engagement by protective antibodies against Ebola virus
Bournazos, S., DiLillo, D. J., Goff, A. J., Glass, P. J., & Ravetch, J. V. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911842116 · Cited by 45
Humanized Mice to Study FcγR Function
Bournazos, S., DiLillo, D. J., & Ravetch, J. V. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_11 · Cited by 39
Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique
McGovern, T. K., Robichaud, A., Fereydoonzad, L., Schuessler, T. F., & Martin, J. G. (2013) · Journal of Visualized Experiments · doi:10.3791/50172-v · Cited by 39
25 Antibody-dependent Enhancement of Infection: A Mechanism for Indirect Virus Entry into CellsPreprint
Halstead, S. B. (1994) · Cold Spring Harbor Monograph Archive · doi:10.1101/087969429.28.493 · Cited by 34
A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters
Fagre, A. C., Manhard, J., Adams, R., Eckley, M., Zhan, S., Lewis, J., Rocha, S. M., Woods, C., Kuo, K., Liao, W., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.614256 · Cited by 33
Rho family GTPases bring a familiar ring to cell wound repair
Verboon, J. M., & Parkhurst, S. M. (2015) · Small GTPases · doi:10.4161/21541248.2014.992262 · Cited by 30
A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamstersPreprint
Fagre, A. C., Manhard, J., Adams, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.25.313601 · Cited by 6

Sorted by citations

Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics
Longo, S. K., Guo, M. G., Ji, A. L., & Khavari, P. A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00370-8 · Cited by 1,059
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881
Self-citation
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
VanBlargan, L. A., Errico, J. M., Halfmann, P., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 690
Self-citation

See all 370

Authors: Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., Case, J. B., Sutton, R. E., Carnahan, R. H., Darling, T. L., Boon, A. C. M., Mack, M., Head, R. D., Ross, T. M., Crowe, J. E., & Diamond, M. S.
Affiliations: Washington University in St. Louis (US)
Vanderbilt University Medical Center (US)
University of Georgia (US)
University Hospital Regensburg (DE)
Corresponding author: Crowe, James E.
Diamond, Michael S.
ORCID: Winkler, Emma S.
Gilchuk, Pavlo
Yu, Jinsheng
Bailey, Adam L.
Chen, Rita E.
Chong, Zhenlu
Zost, Seth J.
Jang, Hyesun
Huang, Ying
Allen, James D.
Case, James Brett
Carnahan, Robert H.
Darling, Tamarand L.
Boon, Adrianus C.M.
Mack, Matthias
Head, Richard D.
Ross, Ted M.
Crowe, James E.
Diamond, Michael S.
Venue: Cell
Publisher: Elsevier BV
Published: 2021-04
Volume: 184
Issue: 7
Pages: 1804-1820.e16
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2021.02.026
PMC: PMC7879018
OpenAlex: W3132982761
Cited by: 366
References: 101
Citations by year: 2026: 13 · 2025: 34 · 2024: 40 · 2023: 69 · 2022: 99 · 2021: 109
FWCI: 25.26
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cell (publishedVersion)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
PubMed Central (submittedVersion)
University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
Funders: NIAID
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, neutralizing monoclonal antibodies, Fc effector functions, passive immunotherapy, COVID-19 pandemic, pulmonary infection, monocytes, CD8+ T cells, innate immune signaling, tissue repair, inflammation, correlates of protection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks